Novonesis (Novozymes) A/S (NSIS-B) - Net Assets

Latest as of September 2025: Dkr10.74 Billion DKK ≈ $1.68 Billion USD

Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) has net assets worth Dkr10.74 Billion DKK (≈ $1.68 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr16.30 Billion ≈ $2.55 Billion USD) and total liabilities (Dkr5.56 Billion ≈ $869.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NSIS-B financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Dkr10.74 Billion
% of Total Assets	65.91%
Annual Growth Rate	4.49%
5-Year Change	-0.6%
10-Year Change	-3.6%
Growth Volatility	12.71

Novonesis (Novozymes) A/S - Net Assets Trend (2002–2024)

This chart illustrates how Novonesis (Novozymes) A/S's net assets have evolved over time, based on quarterly financial data. Also explore Novonesis (Novozymes) A/S assets under control for the complete picture of this company's asset base.

Annual Net Assets for Novonesis (Novozymes) A/S (2002–2024)

The table below shows the annual net assets of Novonesis (Novozymes) A/S from 2002 to 2024. For live valuation and market cap data, see Novonesis (Novozymes) A/S market capitalisation.

Year	Net Assets	Change
2024-12-31	Dkr11.18 Billion ≈ $1.75 Billion	-22.12%
2023-12-31	Dkr14.35 Billion ≈ $2.25 Billion	+0.86%
2022-12-31	Dkr14.23 Billion ≈ $2.23 Billion	+16.57%
2021-12-31	Dkr12.21 Billion ≈ $1.91 Billion	+8.56%
2020-12-31	Dkr11.24 Billion ≈ $1.76 Billion	-2.06%
2019-12-31	Dkr11.48 Billion ≈ $1.80 Billion	+0.37%
2018-12-31	Dkr11.44 Billion ≈ $1.79 Billion	+1.52%
2017-12-31	Dkr11.27 Billion ≈ $1.76 Billion	-4.07%
2016-12-31	Dkr11.74 Billion ≈ $1.84 Billion	+1.31%
2015-12-31	Dkr11.59 Billion ≈ $1.81 Billion	+2.77%
2014-12-31	Dkr11.28 Billion ≈ $1.76 Billion	+1.93%
2013-12-31	Dkr11.07 Billion ≈ $1.73 Billion	+15.66%
2012-12-31	Dkr9.57 Billion ≈ $1.50 Billion	+8.43%
2011-12-31	Dkr8.82 Billion ≈ $1.38 Billion	+12.61%
2010-12-31	Dkr7.84 Billion ≈ $1.23 Billion	+33.93%
2009-12-31	Dkr5.85 Billion ≈ $915.43 Million	+30.72%
2008-12-31	Dkr4.48 Billion ≈ $700.30 Million	+22.06%
2007-12-31	Dkr3.67 Billion ≈ $573.73 Million	+8.08%
2006-12-31	Dkr3.39 Billion ≈ $530.86 Million	-10.57%
2005-12-31	Dkr3.79 Billion ≈ $593.60 Million	-2.52%
2004-12-31	Dkr3.89 Billion ≈ $608.93 Million	-6.78%
2003-12-31	Dkr4.17 Billion ≈ $653.21 Million	-1.72%
2002-12-31	Dkr4.25 Billion ≈ $664.63 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Novonesis (Novozymes) A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2140.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	Dkr82.28 Billion	98.72%
Common Stock	Dkr936.72 Million	1.12%
Other Comprehensive Income	Dkr134.24 Million	0.16%
Other Components	Dkr1.00	0.00%
Total Equity	Dkr83.35 Billion	100.00%

Novonesis (Novozymes) A/S Competitors by Market Cap

The table below lists competitors of Novonesis (Novozymes) A/S ranked by their market capitalization.

Company	Market Cap
American Water Works NYSE:AWK	$24.41 Billion
Cathay Financial Holding Co Ltd Pref A TW:2882A	$24.41 Billion
Banco do Brasil S.A. SA:BBAS3	$24.42 Billion
Swiss Life Holding AG SW:SLHN	$24.44 Billion
Hyundai Electric & Energy Systems Co Ltd KO:267260	$24.39 Billion
Willis Towers Watson PLC NASDAQ:WTW	$24.37 Billion
LPL Financial Holdings Inc NASDAQ:LPLA	$24.34 Billion
KUAISHOU TECHNOLOGY CL.B F:5Y0	$24.31 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Novonesis (Novozymes) A/S's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 13,978,000,000 to 83,350,174,992, a change of 69,372,174,992 (496.3%).
Net income of 305,800,000 contributed positively to equity growth.
Dividend payments of 249,800,000 reduced retained earnings.
New share issuances of 37,800,000 increased equity.
Other comprehensive income increased equity by 473,243,302.
Other factors increased equity by 68,805,131,690.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Dkr305.80 Million	+0.37%
Dividends Paid	Dkr249.80 Million	-0.3%
Share Issuances	Dkr37.80 Million	+0.05%
Other Comprehensive Income	Dkr473.24 Million	+0.57%
Other Changes	Dkr68.81 Billion	+82.55%
Total Change	Dkr-	496.30%

Book Value vs Market Value Analysis

This analysis compares Novonesis (Novozymes) A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.26x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 33.81x to 1.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	Dkr11.20	Dkr378.50	x
2003-12-31	Dkr11.61	Dkr378.50	x
2004-12-31	Dkr10.96	Dkr378.50	x
2005-12-31	Dkr11.22	Dkr378.50	x
2006-12-31	Dkr10.41	Dkr378.50	x
2007-12-31	Dkr11.50	Dkr378.50	x
2008-12-31	Dkr14.17	Dkr378.50	x
2009-12-31	Dkr18.49	Dkr378.50	x
2010-12-31	Dkr24.50	Dkr378.50	x
2011-12-31	Dkr27.53	Dkr378.50	x
2012-12-31	Dkr30.02	Dkr378.50	x
2013-12-31	Dkr34.83	Dkr378.50	x
2014-12-31	Dkr35.77	Dkr378.50	x
2015-12-31	Dkr37.43	Dkr378.50	x
2016-12-31	Dkr38.70	Dkr378.50	x
2017-12-31	Dkr37.87	Dkr378.50	x
2018-12-31	Dkr39.08	Dkr378.50	x
2019-12-31	Dkr40.02	Dkr378.50	x
2020-12-31	Dkr39.83	Dkr378.50	x
2021-12-31	Dkr42.20	Dkr378.50	x
2022-12-31	Dkr49.64	Dkr378.50	x
2023-12-31	Dkr50.28	Dkr378.50	x
2024-12-31	Dkr299.93	Dkr378.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Novonesis (Novozymes) A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.37%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.98%
• Asset Turnover: 0.25x
• Equity Multiplier: 0.18x
Recent ROE (0.37%) is below the historical average (21.69%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	15.93%	11.47%	0.68x	2.06x	Dkr240.80 Million
2003	17.87%	12.67%	0.76x	1.86x	Dkr323.70 Million
2004	20.72%	13.16%	0.84x	1.86x	Dkr410.20 Million
2005	22.89%	13.71%	0.86x	1.94x	Dkr484.90 Million
2006	9.68%	4.78%	0.85x	2.37x	Dkr-10.90 Million
2007	28.49%	14.01%	0.84x	2.43x	Dkr676.30 Million
2008	23.78%	13.04%	0.82x	2.22x	Dkr615.50 Million
2009	20.48%	14.13%	0.78x	1.87x	Dkr610.90 Million
2010	20.63%	16.60%	0.77x	1.61x	Dkr831.60 Million
2011	20.75%	17.39%	0.76x	1.57x	Dkr947.10 Million
2012	21.09%	17.94%	0.74x	1.58x	Dkr1.06 Billion
2013	19.90%	18.73%	0.71x	1.49x	Dkr1.09 Billion
2014	22.42%	20.27%	0.68x	1.64x	Dkr1.40 Billion
2015	24.38%	20.16%	0.79x	1.54x	Dkr1.67 Billion
2016	26.00%	21.57%	0.76x	1.59x	Dkr1.88 Billion
2017	27.71%	21.46%	0.79x	1.63x	Dkr1.99 Billion
2018	28.24%	22.42%	0.73x	1.72x	Dkr2.08 Billion
2019	27.50%	21.94%	0.70x	1.78x	Dkr2.01 Billion
2020	25.15%	20.16%	0.68x	1.83x	Dkr1.70 Billion
2021	26.60%	21.04%	0.60x	2.09x	Dkr1.96 Billion
2022	26.57%	20.94%	0.63x	2.02x	Dkr2.29 Billion
2023	21.63%	16.89%	0.63x	2.03x	Dkr1.63 Billion
2024	0.37%	7.98%	0.25x	0.18x	Dkr-8.03 Billion

Industry Comparison

This section compares Novonesis (Novozymes) A/S's net assets metrics with peer companies in the Specialty Chemicals industry.

Industry Context

Industry: Specialty Chemicals
Average net assets among peers: $836,801,276
Average return on equity (ROE) among peers: 8.24%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Novonesis (Novozymes) A/S (NSIS-B)	Dkr10.74 Billion	15.93%	0.52x	$24.39 Billion
Flügger group A/S (FLUG-B)	$742.17 Million	4.34%	0.48x	$132.73 Million
Hove AS (HOVE)	$71.42 Million	5.01%	0.35x	$23.97 Million
SP Group A/S (SPG)	$1.70 Billion	15.38%	0.86x	$730.92 Million

About Novonesis (Novozymes) A/S

CO:NSIS-B Denmark Specialty Chemicals

Market Cap

$24.39 Billion

Dkr155.92 Billion DKK

Market Cap Rank

#1065 Global

#6 in Denmark

Share Price

Dkr378.50

Change (1 day)

+1.47%

52-Week Range

Dkr342.00 - Dkr487.30

All Time High

Dkr508.57